Oncotelic Therapeutics, Inc.
OTLC · OTCMCIK 908259fmd_1MQY0CFXJRM1BT887PYTDBXZ12Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Jun 30, 2026, 66 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | 2 | – | – | 0 | – | – |
| Cost of revenue | – | – | – | – | – | – | – | – | – | – |
| Realized investment gains (losses) | 0 | – | – | – | – | – | – | 0 | – | 365 |
| Research and development | 9 | 10 | 1 | 1 | 4 | 4 | 1 | 0 | – | 0 |
| Total operating expenses | 14 | 14 | 1 | 4 | 9 | 9 | 10 | 7 | 4 | 3 |
| Operating income | (14) | (14) | (1) | (4) | (8) | (9) | (10) | (7) | (4) | (3) |
| Interest expense | – | – | – | 1 | 2 | 2 | 3 | 1 | – | – |
| Interest and investment income | 0 | 0 | 0 | 0 | – | – | – | – | – | – |
| Other non-operating income (expense) | (0) | (0) | (0) | (2) | (2) | (1) | 14 | (2) | (1) | 364 |
| Income before taxes | – | – | – | – | – | – | – | – | (5) | 361 |
| Income tax expense | – | – | – | – | – | – | – | – | – | 112 |
| Net income from continuing operations | – | – | – | – | – | – | – | – | – | 249 |
| Net income | (14) | (14) | (1) | (7) | (10) | (9) | 5 | (8) | (5) | 249 |
| Net income to common shareholders | – | – | – | – | – | – | – | – | – | – |